Merus N.V.
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
9
Ending by 2030
Jun 2029
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 3 fees due Dec 6 to 27, 2026 · next Dec 6
- 2 fees due Jan 2 to 23, 2027 · next Jan 2
- 2 fees due Feb 22 to 28, 2027 · next Feb 22
- 2 fees due Mar 12 to 29, 2027 · next Mar 12
- 3 fees due Apr 3 to 17, 2027 · next Apr 3
- 1 fee due May 21, 2027The maintenance fee for Methods of Treating a Subject Having an Egfr-Positive And/Or ERBB-3-Positive Tumor (US 11,820,825) comes due May 21, 2027. Unpaid by Nov 22, 2027, it lapses early.
- 1 fee due Jul 16, 2027The maintenance fee for CLEC12AXCD3 Bispecific Antibodies and Methods for the Treatment of Disease (US 11,873,338) comes due Jul 16, 2027. Unpaid by Jan 18, 2028, it lapses early.
- 2 fees due Aug 2, 2027
- 4 fees due Sep 12 to 30, 2027 · next Sep 12
- 1 fee due Oct 9, 2027The maintenance fee for Multivalent Antibody (US 11,952,424) comes due Oct 9, 2027. Unpaid by Apr 10, 2028, it lapses early.
- 1 fee due Nov 12, 2027The maintenance fee for Generation of binding molecules (US 10,647,781) comes due Nov 12, 2027. Unpaid by May 12, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 17, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,765,133 | Antibody Producing Non-Human Mammals In force · High confidence | In force | High confidence | |
| US 9,944,695 | Antibody Producing Non-Human Mammals In force · High confidence | In force | High confidence | |
| US 9,951,124 | Antibody Producing Non-Human Mammals In force · High confidence | In force | High confidence | |
| US 10,605,808 | Antibody Producing Non-Human Animals In force · Low confidence | In force | Low confidence | |
| US 10,966,411 | Antibody producing non-human mammals In force · High confidence | In force | High confidence | |
| US 11,237,165 | Antibody Producing Non-Human Animals In force · Low confidence | In force | Low confidence | |
| US 11,559,049 | Antibody Producing Non-Human Animals In force · High confidence | In force | High confidence | |
| US 11,925,174 | Antibody Producing Non-Human Animals In force · High confidence | In force | High confidence | |
| US 11,785,924 | Antibody Producing Non-Human Animals In force · High confidence | In force | High confidence | |
| US 9,145,588 | Generation of Binding Molecules In force · High confidence | In force | High confidence |
Also on record, not counted in the 51: 2 patents in force now held by others · 11 ended at full term · 1 surrendered on reissue. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
48 pending · 6 abandoned · 6 no status recorded